Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy

Dermatologic Surgery

Volumn 33, Issue SUPPL. 1, 2007, Pages

  Lee, Soo Keun ^a  

^a Mein Skin Clinic   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BOTULINUM TOXIN A;

ADULT; ANTIBODY RESPONSE; ARTICLE; CASE REPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNITY; MASSETER MUSCLE; MUSCLE HYPERTROPHY; PARESIS; PRIORITY JOURNAL; TREATMENT FAILURE;

ADULT; ANTIBODIES; ANTIBODY FORMATION; BOTULINUM TOXIN TYPE A; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTROPHY; MASSETER MUSCLE; NEUROMUSCULAR AGENTS;

EID: 33845982231     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2006.32340.x     Document Type: Article

References (26)

1. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992;18:17-21.
2. Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg 2003;29:477-83.
3. Kim HJ, Yum KW, Lee SS, et al. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg 2003;29:484-9.
4. Kim NH, Chung JH, Park RH, Park JB. The use of botulinum toxin type A in aesthetic mandibular contouring. Plast Reconstr Surg 2005;115:919-30.
5. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A. efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999;246:265-74.
6. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003;60:1186-8.
7. Dressler D. Clinical presentation and management of antibodyinduced failure of botulinum toxin therapy. Mov Disord 2004;19:(8 Suppl):S92-S100.
8. Dressler D. New formulation of BOTOX: complete antibody-induced therapy failure in hemifacial spasm. J Neurol 2004;251:360.
9. Frueh BR, Felt DP, Wojno TH, Musch DC. Treatment of blepharospasm with botulinum toxin: a preliminary report. Arch Ophthalmol 1984;102:1464-8.
10. Dressler D. Botulinum toxin therapy failure: causes, evaluation procedures and management strategies. Eur J Neurol 1997;4:(2 Suppl):S67-70.
11. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-6.
12. Dressler D. Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol 2000;247:809-10.
13. Atassi MZ. Basic immunological aspects of botulinum toxin therapy. Mov Disord 2004;19:(8 Suppl):S68-84.
14. Kessler KR, Benecke R. The EDB test - a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 1997;12:95-9.
15. Dressler D, Bigalke H, Rothwell JC. The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans. J Neurol 2000;247:630-2.
16. Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 1998;50:1624-9.
17. Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry 1999;66:612-6.
18. Braune C, Erbguth F, Birklein F. Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: measured by sudometry. Br J Dermatol 2001;144:111-7.
19. Voller B, Moraru E, Auff E, et al. Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A. Mov Disord 2004;19:943-7.
20. Sesardic D, Jones RG, Leung T, et al. Detection of antibodies against botulinum toxins. Mov Disord 2004;19:(8 Suppl):S85-91.
21. Dressler D, Dirnberger G. Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay. Eur Neurol 2001;45: 257-60.
22. Göschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies - therapeutic consequences. Exp Neurol 1997;147:96-102.
23. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord 2004;19:(8 Suppl):S109-15.
24. Carruthers A, Carruthers J, Cohen J. A prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatol Surg 2003;29:461-7.
25. Carruthers J, Carruthers A. Aesthetic botulinum A toxin in the mid and lower face and neck. Dermatol Surg 2003;29:468-76.
26. Lee SK. Newly-developed antibody to BTX-A in a patient with squared face [in Korean]. Korean J Dermatol 2005;43:(1 Suppl.): S141-2.